Winning ENTA Stock Forecast: Enanta Pharmaceuticals shows constant promising R&D results

Winning ENTA Stock Forecast: Enanta Pharmaceuticals shows constant promising R&D results

Enanta also has three clinical stage internally invented and wholly owned programs in areas of high unmet need namely NASH, PBC and RSV. And I would note, all three of these development programs now have fast track designation.

  • Jay Luly, President and CEO

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493).

Read More

VRX Stock Forecast: Valeant Veers Away From Scandals, Rebrands Company

  This article was written by Julia Masch, a Financial Analyst at I Know First.




  Summary:

  • Q1 Highlights + Product Pipeline
  • Scandals + Valeant's Valiant Name Change
  • Current I Know First Forecast For VRX
premiumRead The Full Premium Article Subscribe to receive exclusive PREMIUM content here

Best Pharma Stocks Based on Artificial Intelligence: Returns up to 40.28% in 14 Days

Pharma Stocks Forecast Package Name: Pharma Stocks
Recommended Positions: Long
Forecast Length: 14 Days (05/30/2018 - 06/13/2018)
I Know First Average: 11.62%

Read The Full Forecast

Best Pharma Stocks

Best Pharma Stocks Based on Artificial Intelligence: Returns up to 15.78% in 3 Days

Pharma Stocks Forecast Package Name: Pharma Stocks
Recommended Positions: Long
Forecast Length: 3 Days (06/10/2018 - 06/13/2018)
I Know First Average: 3.66%

Read The Full Forecast

Best Pharma Stocks

Best Pharma Stocks Based on Data Mining: Returns up to 8.83% in 3 Days

Pharma Stocks Forecast Package Name: Pharma Stocks
Recommended Positions: Long
Forecast Length: 3 Days (06/08/2018 - 06/12/2018)
I Know First Average: 4.01%

Read The Full Forecast

Best Pharma Stocks

Best Pharma Stocks Based on Algo Trading: Returns up to 22.43% in 7 Days

Pharma Stocks Forecast Package Name: Pharma Stocks
Recommended Positions: Long
Forecast Length: 7 Days (05/30/2018 - 06/06/2018)
I Know First Average: 7.46%

Read The Full Forecast

Best Pharma Stocks

Best Pharma Stocks Based on Machine Learning: Returns up to 54.97% in 7 Days

Pharma Stocks Forecast Package Name: Pharma Stocks
Recommended Positions: Long
Forecast Length: 7 Days (05/09/2018 - 05/16/2018)
I Know First Average: 13.70%

Read The Full Forecast

Best Pharma Stocks
Pages:1234567...20»